Wall Street analyst estimates for Predictive Oncology Inc. (POAI): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Predictive Oncology Inc. (POAI), an organization driven by expertise and data, is dedicated to pioneering individualized cancer treatments through the application of artificial intelligence, primarily within the United States. The company conducts its operations across four distinct divisions: Helomics, zPREDICTA, Soluble, and Skyline.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 0 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 1 |
| Avg rating (1-5) | 0.00 |
Valuation Ratios
| Price / Book | 2.84 |
| EV / EBITDA | -0.50 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $456495 | $654836 | $1.4M | $1.4M | $1.3M | $1.4M | $1.5M | $1.6M | $1.6M | $125284 |
| Cost of Revenue | $181620 | $148045 | $415764 | $531810 | $447192 | $487024 | $505107 | $609212 | $826137 | $72622 |
| Gross Profit | $274875 | $506791 | $995891 | $879755 | $805080 | $933656 | $1.0M | $1.0M | $797680 | $52662 |
| Research & Development | $406000 | $289000 | $1.9M | $3.0M | $372710 | $315850 | $320320 | $122307 | $25987 | $2.1M |
| Selling, General & Admin | $5.6M | $8.3M | $7.0M | $11.7M | $10.9M | $11.7M | $12.5M | $9.1M | $8.9M | $26.3M |
| Operating Expenses | $6.8M | $8.3M | $8.9M | $23.5M | $26.2M | $21.4M | $27.0M | $13.1M | $11.7M | $28.5M |
| Operating Income | -$6.5M | -$7.7M | -$7.9M | -$22.6M | -$25.4M | -$20.4M | -$26.0M | -$12.1M | -$10.9M | -$28.4M |
| EBITDA | -$6.4M | -$6.0M | -$7.7M | -$13.1M | -$11.5M | -$12.1M | -$14.0M | -$11.8M | -$10.2M | -$232.2M |
| Interest Expense | $3 | 0 | 0 | 0 | 0 | 0 | $10.7M | 0 | 0 | 0 |
| Pre-tax Income | -$6.5M | -$7.7M | -$10.1M | -$19.4M | -$25.9M | -$20.3M | -$25.7M | -$12.0M | -$10.9M | -$232.9M |
| Income Tax | 0 | $50503 | 0 | 0 | 0 | -$661658 | 0 | 0 | 0 | 0 |
| Net Income | -$6.5M | -$7.7M | -$10.1M | -$19.4M | -$25.9M | -$19.7M | -$25.7M | -$14.0M | -$12.2M | -$233.1M |
| EPS | $-462.28 | $-188.69 | $-157.40 | $-137.14 | $-44.25 | $-7.16 | $-6.98 | $-3.48 | $-2.24 | $-13.37 |
| EPS (Diluted) | $-462.28 | $-188.69 | $-157.40 | $-137.20 | $-44.25 | $-7.20 | $-6.98 | $-3.48 | $-2.24 | $-13.37 |
| Shares Outstanding (Diluted) | $14115 | $31815 | $64080 | $143505 | $597510 | $2.7M | $3.7M | $4.0M | $5.5M | $17.4M |
Price
| Price | $4.91 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | US |
Related companies: AIM · AMIX · BNGO · CYCN · GBS · HSCS · KTTA
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of POAI: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks